Exclusive Summary

• As a WHO Essential Medicine and foundational first-line chemotherapy for both colorectal and gastric cancers, Oxaliplatin serves a massive and rigid global market covering over 2.9 million new patients annually.
• Operating in a fully mature post-patent market, leveraging authentic Chinese API-to-FDF manufacturing efficiency provides distributors with unparalleled cost advantages and competitiveness for national tenders.
• Since complex cytotoxic oncology injectables frequently suffer from regional supply shortages, establishing a highly reliable supply of the standard 50mg presentation empowers partners to capture profitable market share gaps left by competitor stock-outs.